Antares pharma announces submission of ind application for atrs-1902 for adrenal crisis rescue

Ewing, n.j., june 22, 2021 (globe newswire) -- antares pharma, inc. (nasdaq: atrs) (“the company”), a specialty pharmaceutical company, today announced that it has submitted an investigational new drug (ind) application with the u.s. food and drug administration (fda) for the initiation of a phase 1 clinical study of atrs-1902 for adrenal crisis rescue. the ind application for atrs-1902, and its corresponding development program, supports a proposed indication for the treatment of acute adrenal insufficiency, known as adrenal crisis, in adults and adolescents, using a novel proprietary auto-injector platform to deliver hydrocortisone.
ATRS Ratings Summary
ATRS Quant Ranking